[THE INVESTOR] On Oct. 19, KD Pharm (011040) declined 0.83% to 17,900 won (US$15.94). It had declined 0.28% through the past month. Standard deviation, which indicates risk, records 1.3% over the same period over one month.


Compared with its close competitors within the same industry, KOSDAQ, KD Pharm was not only satisfactory in investment return among its peer group, but its volatility was also the lowest. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -0.2%. In spite of stock price decline, the return-on-risk remain high with the lowest volatility. Moreover, compared with the KOSDAQ industry, the return-on-risk is much better than the industrial mean, -0.3, and thus the industrial comparison performance was positive.

While institutions have been buying KD Pharm during the past five trading days, foreigners have been selling during the past nine trading days. As a shareholding sum by investor group for the past four weeks, institutions have bought 50,451 shares with trending trade and individuals have bought 892 shares with an increasing position. However, during the same period, foreigners have sold 51,343 shares with maintenance of a selling position.

Cumulated shareholdings per investor group (1Mo) Total shareholdings per investor group

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.